BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11221516)

  • 1. Update of diagnostic and prognostic markers in cutaneous malignant melanoma.
    Reed JA; Albino AP
    Clin Lab Med; 2000 Dec; 20(4):817-38. PubMed ID: 11221516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update of diagnostic and prognostic markers in cutaneous malignant melanoma.
    Reed JA; Albino AP
    Dermatol Clin; 1999 Jul; 17(3):631-43. PubMed ID: 10410863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
    Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
    Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
    Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
    J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular diagnostics in melanoma.
    Carlson JA; Ross JS; Slominski A; Linette G; Mysliborski J; Hill J; Mihm M
    J Am Acad Dermatol; 2005 May; 52(5):743-75; quiz 775-8. PubMed ID: 15858465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiling of primary cutaneous melanoma.
    Winnepenninckx V; Van den Oord JJ
    Verh K Acad Geneeskd Belg; 2007; 69(1):23-45. PubMed ID: 17427873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma.
    Ricaniadis N; Kataki A; Agnantis N; Androulakis G; Karakousis CP
    Eur J Surg Oncol; 2001 Feb; 27(1):88-93. PubMed ID: 11237497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical detection of XIAP in melanoma.
    Emanuel PO; Phelps RG; Mudgil A; Shafir M; Burstein DE
    J Cutan Pathol; 2008 Mar; 35(3):292-7. PubMed ID: 18251743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma.
    Scala S; Ottaiano A; Ascierto PA; Cavalli M; Simeone E; Giuliano P; Napolitano M; Franco R; Botti G; Castello G
    Clin Cancer Res; 2005 Mar; 11(5):1835-41. PubMed ID: 15756007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HSP-70, C-myc and HLA-DR expression in patients with cutaneous malignant melanoma metastatic in lymph nodes.
    Kalogeraki A; Garbagnati F; Darivianaki K; Delides GS; Santinami M; Stathopoulos EN; Zoras O
    Anticancer Res; 2006; 26(5A):3551-4. PubMed ID: 17094481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desmoplastic malignant melanoma: a clinicopathologic analysis of 113 cases.
    de Almeida LS; Requena L; Rütten A; Kutzner H; Garbe C; Pestana D; Gomes MM
    Am J Dermatopathol; 2008 Jun; 30(3):207-15. PubMed ID: 18496419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression pattern of the lymphatic and vascular markers VEGFR-3 and CD31 does not predict regional lymph node metastasis in cutaneous melanoma.
    Wobser M; Siedel C; Schrama D; Bröcker EB; Becker JC; Vetter-Kauczok CS
    Arch Dermatol Res; 2006 Feb; 297(8):352-7. PubMed ID: 16395613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KBA.62: a useful marker for primary and metastatic melanomas.
    Pagès C; Rochaix P; al Saati T; Valmary-Degano S; Boulinguez S; Launay F; Carle P; Lauwers F; Payoux P; Le Guellec S; Brousset P; Lamant L
    Hum Pathol; 2008 Aug; 39(8):1136-42. PubMed ID: 18495211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic factors in thin cutaneous malignant melanoma].
    Massi D; Franchi A; Santucci M
    Pathologica; 2002 Dec; 94(6):282-9. PubMed ID: 12540991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression.
    Redondo P; Lloret P; Idoate M; Inoges S
    Clin Exp Dermatol; 2005 Sep; 30(5):541-5. PubMed ID: 16045689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients.
    Quaglino P; Osella-Abate S; Cappello N; Ortoncelli M; Nardò T; Fierro MT; Cavallo F; Savoia P; Bernengo MG
    Melanoma Res; 2007 Apr; 17(2):75-82. PubMed ID: 17496782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromogenic in situ hybridization analysis of melastatin mRNA expression in melanomas from American Joint Committee on Cancer stage I and II patients with recurrent melanoma.
    Hammock L; Cohen C; Carlson G; Murray D; Ross JS; Sheehan C; Nazir TM; Carlson JA
    J Cutan Pathol; 2006 Sep; 33(9):599-607. PubMed ID: 16965333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor characteristics involved in the metastatic behaviour as an improvement in primary cutaneous melanoma prognostics.
    Goldmann T; Ribbert D; Suter L; Brode M; Otto F
    J Exp Clin Cancer Res; 1998 Dec; 17(4):483-9. PubMed ID: 10089072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhabdomyosarcomatous (myoblastic?) phenotype of metastatic malignant melanoma. A case report.
    Pasz-Walczak G; Jesionek-Kupnicka D; Kubiak R; Biernat W; Sygut J; Kordek R
    Pol J Pathol; 2002; 53(2):97-100. PubMed ID: 12140874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
    Liu B; Ma J; Wang X; Su F; Li X; Yang S; Ma W; Zhang Y
    Anat Rec (Hoboken); 2008 Oct; 291(10):1227-35. PubMed ID: 18561194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.